profit from every $100 of sales.
$0$100
Savara
$5.05+4.55% today
+27.8% in 1 year
1-year low $3.951-year high $6.94
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Savara sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$119 million of profit last year.
SalesProfit
Savara vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Savara | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Savara's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -38 | -59 | -102 | -123 | |
| -38 | -59 | -102 | -123 | |
| -38 | -55 | -96 | -119 | |
| -0.25 | -0.33 | -0.48 | -0.53 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 140 | 178 | 213 | 253 |
| Cash | 52 | 27 | 15 | 33 |
| Total debt | 26 | 26 | 27 | 30 |
| Total liabilities | 32 | 37 | 41 | 50 |
| 108 | 140 | 171 | 203 | |
| 153 | 165 | 198 | 222 | |
| -22.4% | -28.0% | -40.8% | -41.6% | |
| -35.4% | -39.0% | -55.9% | -58.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -35 | -51 | -89 | -101 | |
| 0 | 0 | 0 | 0 | |
| -35 | -51 | -89 | -101 | |
| Dividends paid | – | – | – | – |
| 0 | 1 | 1 | 5 | |
| 2 | 4 | 10 | 14 |
Valuation
- –
- –
- –
- 7.6×
- –
- –
- –
- -9.8%
- -11.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -65.1%
- -37.2%
- -87.2%
- -58.4%
- -65.1%
- –
Growth
- –
- –
- −13.4%
- –
- +13.5%
Financial health
- 0.1×
- 0.17
- 13.6%
- –
- 13.47
- 13.47
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 948
Bottom 21%of 871
Bottom 12%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.15 | -0.14 | −7.1% |
| Mar 13, 2026 | -0.13 | -0.12 | −8.3% |
| Nov 12, 2025 | -0.14 | -0.13 | −7.7% |
| Aug 13, 2025 | -0.14 | -0.12 | −16.7% |
| May 13, 2025 | -0.12 | -0.12 | +0.0% |
| Mar 27, 2025 | -0.13 | -0.11 | −18.2% |
| Nov 12, 2024 | -0.11 | -0.11 | +0.0% |
| Aug 12, 2024 | -0.12 | -0.11 | −9.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
22No pass
Benjamin Graham
39No pass
Philip Fisher
33No pass
Peter Lynch
57No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
26No pass
Questions about Savara
Is Savara a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Savara AI analysis
What does Savara do?
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. It is in Biotechnology.
Does Savara pay a dividend?
No. Savara does not pay a dividend at the moment; in 2025 it returned $5.14 million to shareholders by buying back its own shares.
Is Savara stock halal?
Yes. Savara passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Savara stock done over the past year?
Up 27.8% over the past twelve months, to $5.05. It traded between $3.95 and $6.94 and is 27.2% below its high.
Who are Savara's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Savara's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.